- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03002506
Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns
March 1, 2021 updated by: Texas Tech University Health Sciences Center
This study will help provide information about how patients with burn handle two antibiotics (ceftolozane and tazobactam) and use that information to guide dosing recommendations for these patients.
The 12 patients who complete the study will receive a single dose of 3 grams ceftolozane/tazobactam intravenously.
We will collect blood and urine samples to determine how much of each antibiotic is in the body and urine at various times over a 24 hour period.
This information will be used with previously published information from microbiology laboratories to perform simulations that will provide recommendations on optimal dosing recommendations of these antibiotics in patients with burns.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
A single dose pharmacokinetic study of ceftolozane and tazobactam will be conducted in patients with burns at the Burn Center at University Medical Center.
A total of 12 adults aged 18 to 80 years with >/= 20% percent total body surface area burned will be required to complete the study.
A single intravenous dose of ceftolozane and tazobactam of 2 grams/1 gram will be administered over 60 minutes and whole blood will be obtained predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours following the start of infusion.
Urine samples (5 ml) will be collected from a urine collection bag (if the patient has urinated) at the following timepoints: 0-0.5, 0.5-1, 1-2, 2-4, 4-8, 8-12, and 12-24 hours for analysis of ceftolozane and tazobactam content.
Urine for collected during each time period will be measured to determine urine volume for urine clearance calculations.
The volume of urine in the urine over the entire 24 hour period and an aliquot sent for analysis of urine creatinine content to determine the patient's 24 hour creatinine clearance.
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Lubbock, Texas, United States, 79415
- University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female subjects, ages 18-80 years, of all racial and ethnic origins.
- Non-English Spanish speakers will be included in the study.
- We are recruiting 12 patients with thermal burn injuries (percent total body surface area burned >/= 20%). Patients will be at least five days from the date of the burn injury.
- Patients will have central venous or arterial line access.
- Patients will be already be receiving standard of care antimicrobial therapy for a suspected infection.
Exclusion Criteria:
- Pregnant or nursing or unwilling to use a reliable contraception method during the study. The effects of ceftolozane and tazobactam on pregnancy are unknown. In addition, the metabolic changes that accompany pregnancy may alter the concentration-time profile of ceftolozane and tazobactam, so that the pregnancy and post-partum state would be a confounding variable.
- Abnormal liver function tests: transaminases >10 times upper limit of normal, Alkaline phosphatase >5 times upper limit of normal, total bilirubin >5 times upper limit of normal.
- History of allergies to beta-lactam antibiotics.
- Patients unwilling to comply with study procedures.
- Current or previous participation within 28 days of enrollment in another research study that involves the use of medication, contrast, or any other compound that may alter blood count and/or blood chemistry (liver function, kidney function or electrolyte balance), unless waved by principal investigator (PI).
- Donation of 450mL (one unit) of blood or more within 8 weeks (56 days) prior to study enrollment, unless waved by PI.
- Creatinine clearance < 30 ml/min as estimated by the Cockcroft-Gault equation.
- Patients who are receiving piperazillin/tazobactam or have received piperacillin/tazobactam within the past 48 hours.
- Patients who are receiving vasopressors.
- Patients with a total body weight < 60 kg or > 130 kg.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ceftolozane/tazobactam
One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.
|
Single dose of 2 grams/1 gram intravenously administered over 60 minutes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ceftolozane Clearnace
Time Frame: 24 hours
|
Liters/hour (continuous values)
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Ronald G Hall, PharmD, Texas Tech University HSC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 21, 2017
Primary Completion (Actual)
June 1, 2020
Study Completion (Actual)
June 30, 2020
Study Registration Dates
First Submitted
December 21, 2016
First Submitted That Met QC Criteria
December 21, 2016
First Posted (Estimate)
December 23, 2016
Study Record Updates
Last Update Posted (Actual)
March 2, 2021
Last Update Submitted That Met QC Criteria
March 1, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 070619
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burns
-
MediWound LtdUnknownBurns, Upper Extremity | Burns, Lower ExtremitySlovakia
-
Singapore General HospitalUnknownAcute Thermal BurnsSingapore
-
American Scitech InternationalJohnson & JohnsonUnknownBurns | Electric BurnsUnited States
-
RenovaCare, IncActive, not recruitingBurns | Burns Second Degree | Burns Deep Second DegreeUnited States
-
MediWound LtdCompletedThermal BurnsUnited States, Israel, Belgium, Czechia, Georgia, Germany, Italy, Romania
-
Sun Yat-sen UniversityCompleted
-
The Hong Kong Polytechnic UniversityCompleted
-
MediWound LtdActive, not recruitingThermal BurnsUnited States, United Kingdom, Spain, Georgia, Belgium, Poland, Germany, Hungary, India, Italy, Netherlands, Romania, Slovakia, Ukraine
-
ShiCang YuNot yet recruitingLarge Area BurnsChina
-
St. Justine's HospitalRecruiting
Clinical Trials on Ceftolozane/tazobactam
-
Cubist Pharmaceuticals LLCCompletedProven or Suspected Gram-negative Bacterial Infection | Peri-operative Prophylaxis
-
Cubist Pharmaceuticals LLCCompleted
-
Weill Medical College of Cornell UniversityMerck Sharp & Dohme LLCRecruitingPneumonia | Hematologic Malignancy | Pseudomonas AeruginosaUnited States
-
Cubist Pharmaceuticals LLCTerminatedVentilator-Associated Pneumonia (VAP)United States, Australia, New Zealand
-
Hamad Medical CorporationMerck Sharp & Dohme LLCWithdrawnHematologic Cancer | Neutropenia, FebrileQatar
-
Beneficência Portuguesa de São PauloMerck Sharp & Dohme LLCNot yet recruiting
-
Temple UniversityUnknownPseudomonas Infections | Pseudomonas AeruginosaUnited States
-
The University of QueenslandMerck Sharp & Dohme LLCWithdrawnBacteremia Caused by Gram-Negative BacteriaSpain, Australia, Singapore, Italy, Saudi Arabia
-
Fundación Pública Andaluza para la gestión de la...Unknown
-
Sunshine Coast Hospital and Health ServiceThe Prince Charles Hospital; MaterNot yet recruitingBronchiectasis | Cystic Fibrosis | Pseudomonas Aeruginosa | Burkholderia Cepacia Infection